WHO Health Technology Access Programme
The World Health Organization’s (WHO) Health Technology Access Programme (HTAP) is a groundbreaking initiative designed to bridge the global health technology access gap. By expanding regional innovation and manufacturing capacity, HTAP aims to enhance health security and address unmet health needs worldwide.
Program Overview
HTAP is a collaborative and demand-driven program that selects priority health technologies and mobilizes partners to support their development, transfer, and sustainable production. The initiative covers both pandemic preparedness and public health priorities outside of emergencies, ensuring a comprehensive approach to global health security.
Key Focus Areas
- mRNA Technology Transfer Programme: HTAP has initially focused on mRNA vaccines and diagnostics. The mRNA Technology Transfer Programme works with 15 selected manufacturers from low- and middle-income countries (LMICs) to establish sustainable, locally owned mRNA manufacturing capabilities.
- Technology Transfer and Licensing: HTAP facilitates technology transfer sublicensing agreements, providing manufacturers in LMICs with the rights, know-how, and materials to manufacture critical health products. A notable example is the agreement with SD Biosensor for rapid diagnostic testing technology.
- Partnerships and Collaborations: The program partners with public R&D institutes, such as the Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST) in India and the University of Cape Town (UCT) in South Africa, to expand equitable access to innovative technologies.
Funding and Support
HTAP is primarily funded by the Government of Belgium, the European Union, the Republic of France, and the Government of Spain. While the WHO is responsible for the content, it does not necessarily reflect the views of the donors.
Recent Developments
- May 9, 2025: WHO and Medicines Patent Pool announced a sublicensing agreement for rapid diagnostic test technology.
- February 26, 2025: A new partnership with the Indian Institute was established to advance technology transfer and health equity.
- January 31, 2024: WHO and MPP announced a technology transfer license to enable greater patient access to multiple essential diagnostics.
HTAP represents a significant step forward in global health equity, leveraging WHO’s expertise and convening power to coordinate efforts across the health technology landscape. By fostering research and development, securing technology transfers, and promoting sustainable production, HTAP is poised to make a lasting impact on global health security.
